Core Scientific Targets 1.5 GW in Texas AI Expansion

NEW YORK, May 2 —

Core Scientific spent March and April 2026 doing three things at once: announcing a 1.5-gigawatt AI data center expansion at its Pecos, Texas campus, filing two separate material financing agreements with undisclosed terms, and watching a company officer sell shares every single week as the stock climbed 37%. Fifth Third Bancorp used that same stretch to open a $59.8 million position. One institution buying, one officer selling — that divide is the CORZ debate in a sentence.

The Build

The Pecos campus expansion is Core Scientific's central argument to equity investors. News reports from around April 30 describe the company targeting a 1.5-gigawatt buildout of the site for AI infrastructure. A separate report from around April 27 notes the campus was already being marketed for lease, with capacity targeted for early 2027.

That sequencing is standard in large-scale data center development: pre-lease before pouring concrete, sign anchor tenants before committing full capital. At 1.5 gigawatts, this would rank among the largest AI infrastructure campuses in the country. The tenants who sign those leases will determine whether this is a productive asset or a costly bet on demand that hasn't arrived yet.

Two investor-facing disclosures filed in late April under Regulation FD suggest Core Scientific is actively pitching the story. The April 27 filing and the April 21 filing are consistent with press releases or investor event disclosures. A company with a 1.5-gigawatt story is telling it.

The Debt Behind the Dream

While the expansion narrative was building, so was the obligation stack. Core Scientific filed 8-Ks on March 6 and March 23, each disclosing Items 1.01 and 2.03 under SEC taxonomy. Item 1.01 signals a Material Definitive Agreement. Item 2.03 means the Creation of a Material Direct Financial Obligation. Twice in six weeks. Terms undisclosed in both filings.

Capital-intensive infrastructure companies take on financing constantly. That's not inherently alarming. But at a company running negative $539 million in trailing free cash flow against $320 million in trailing revenue, the capital markets are not supplemental. They are structural. A 1.5-gigawatt buildout does not get financed on operating cash flow that is deeply negative. The March filings confirm Core Scientific is adding to its obligations. What those filings do not disclose: the interest rate, the maturity schedule, or the covenant structure.

At a 48.5x forward earnings multiple, investors are paying for growth they can see but financing they cannot. The terms of both March obligations remain undisclosed.

The Selling Pattern

Todd Duchene, a Core Scientific officer, executed six open-market sales between April 1 and April 27, totaling 50,000 shares for approximately $911,000 in proceeds, all under a pre-arranged 10b5-1 trading plan. His first sale was 10,000 shares at $15.25 on April 1. His last was 10,000 shares at $20.94 on April 27. The price at which he sold rose approximately 37% over those 27 days.

The 10b5-1 caveat is legitimate: sales scheduled in advance cannot, by design, trade on inside information, and plans cannot respond to news in real time. But plans can be canceled. The weekly cadence ran without interruption through a period when the company was announcing a 1.5-gigawatt expansion, filing material obligations, and running active investor outreach. The plan kept running.

The full open-market picture provides some counterweight. Eric Stanton Weiss purchased 7,000 shares at $14.53 on March 9 for approximately $102,000, the only open-market buy in the 90-day window. Net open-market transactions: roughly $102,000 in purchases against $911,000 in sales. A nine-to-one ratio in the direction of selling.

The Multiple and the Miss

CORZ shares at $20.35 imply a $6.42 billion market capitalization and a forward P/E of 48.5x. The average analyst price target is $26.55, roughly 30% above current levels. Fifth Third's $59.8 million entry, reported May 2, is institutional confirmation that serious capital is willing to pay that premium. A position of that size is a view, not a passive rebalance.

The earnings record does not support the multiple. In the most recently reported quarter, EPS came in at negative $0.13 against a consensus estimate of $0.02. Two quarters prior, the miss was wider: negative $0.20 against a $0.07 estimate. The lone beat in the three-quarter window was a $0.07 print against a $0.01 estimate. Two misses and one beat, on a premium multiple, on a revenue base that contracted 16% over the trailing twelve months.

A 17.1% gross margin is lean for a company priced as a technology infrastructure compounder. The AI campus narrative argues margins expand once Pecos leases start generating contracted revenue. That may prove correct. The trailing financials do not yet show it.

What Comes Next

The early 2027 capacity target is the first hard checkpoint. If Core Scientific announces signed anchor leases for the Pecos expansion over the next two to three quarters, the investment thesis sharpens. Contracted AI infrastructure revenue is priced on a different basis than spot-exposed, declining-revenue data operations. A credible tenant announcement reprices the stock quickly.

If the Pecos leases stay quiet into late 2026, the gap between the narrative and the trailing financials widens. A company burning $539 million in free cash flow on $320 million in declining revenue needs either contracted forward revenue or continued capital infusions to hold its current valuation. Right now it is pursuing both simultaneously, with the terms of the financing still undisclosed. When those terms surface in subsequent SEC filings or quarterly earnings, they will either validate the expansion economics or complicate them.

The bull and bear cases carry equal weight here. The AI expansion thesis, the Fifth Third institutional entry, and analyst targets 30% above current prices make the bull case coherent. The persistent officer selling, undisclosed material obligations, negative free cash flow, and a 48.5x multiple against a two-miss earnings record make the bear case equally coherent. The next filing that matters is either a signed Pecos lease or a disclosed debt structure. The filing record, for now, tells a story of ambition that has not yet reached the income statement.

Run the free Core Scientific, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Is Core Scientific (CORZ) stock a buy right now?

Per the analysis above, the bull and bear cases are evenly matched at current prices. A $26.55 average analyst target is 30% above current levels and Fifth Third's $59.8 million institutional position supports the bull case, but negative $539 million in free cash flow, a 16% revenue decline, and persistent insider selling weigh against the 48.5x forward multiple.

What is Core Scientific's AI expansion plan?

Per reports from around April 30, 2026, Core Scientific is targeting a 1.5-gigawatt buildout of its Pecos, Texas campus for AI data center infrastructure. The campus was already being marketed for lease as of around April 27, with capacity targeted for early 2027, as analyzed in this report.

Are Core Scientific insiders buying or selling stock?

Net selling by a wide margin, per Form 4 filings reviewed above. Officer Todd Duchene sold 50,000 shares for approximately $911,000 across six weekly open-market tranches from April 1 to April 27, 2026. The only open-market purchase in the 90-day window was a 7,000-share buy by Eric Stanton Weiss in March, totaling roughly $102,000.

Did Core Scientific take on new debt recently?

Per SEC filings covered in this report, Core Scientific filed 8-Ks on March 6 and March 23, 2026, each disclosing the creation of a material direct financial obligation under Item 2.03. The size and terms of both obligations were not publicly disclosed in those filings.

What is Core Scientific's revenue and free cash flow?

Core Scientific's trailing twelve-month revenue was approximately $320 million, down 16% year-over-year, with a 17.1% gross margin and trailing free cash flow of negative $539 million, as detailed in the financial analysis above.